TRANSLATIONAL ONCOLOGY PROGRAM

转化肿瘤学（TO）项目的使命是开发促进相互作用的临床试验 在基础科学家、转化科学家和临床医生之间进行合作，以促进改善临床结果。 在上一次审查期间，该方案分为以下三个专题领域： 在特定疾病工作组中强调：（1）开发和开展早期临床试验， 目标是将研究结果转化为合作小组或第三阶段环境;（2）促进纳入预测性 临床试验中的预后生物标志物谱;（3）开发与 抗血管生成剂、信号传导途径和活性氧（ROS）。为了促进方案间 和程序内的相互作用和翻译活动，疾病特异性翻译 最近成立了黑色素瘤、乳腺癌、GI、前列腺和宫颈癌/妇科工作组（TWG） 癌的临床试验耦合到翻译终点已经开发，通过跨学科 与其他项目的合作，包括肿瘤成像（新辅助乳腺）和癌细胞生成， 信号传导（CML，前列腺）。在过去的五年里，我们的计划一直专注于临床研究的应计费用 试验，包括假设驱动的，制药商发起的试验（HDII），合作组，和药物 赞助的试验。重点一直放在HDII试验，以利用UCI丰富的综合癌症 集中资源开发癌症护理的新方法。在过去六年中，HDII应计费用 从2002-2004年的60个急剧增加到2005-2007年的175个。总体干预性临床试验累积， 不包括化学预防试验，2002-2003年为142项，2004-2005年增加到218项，2004-2005年迄今为387项。 2005-2007年，特别重要的是，应计费用的增长与转化终点有关， 同行评审资金和增加在高影响力期刊上的出版物数量。 TO计划有25名成员，代表八个部门和一所学校，并有2，024，203美元， 直接与癌症相关的同行评审资金，其中10个项目由NCI资助，直接总额为 118万7498美元在2007年，委员共出版了71份刊物，其中62份与癌症有关， 其中44%为内部相关，16%为内部相关。

The Translational Oncology (TO) Program's mission is to develop clinical trials that promote interaction between basic scientists, translational scientists, and clinicians to facilitate improved clinical outcomes. During the last review period the Program was organized into the following three thematic areas that are emphasized in disease-specific working groups: (1) Develop and carry out early phase clinical trials with a goal to translate findings into the cooperative group or phase III setting; (2) Facilitate inclusion of predictive and prognostic biomarker profiles in clinical trials; (3) Develop novel therapeutic approaches related to antiangiogenesis agents, signaling pathways and reactive oxygen species (ROS). In order to promote interprogrammatic and intra-programmatic interactions and translational activities, disease specific translational working groups (TWGs) were recently established for melanoma, breast, Gl, prostate and cervical/GYN cancers. Clinical trials coupled to translational endpoints have been developed through inter-programatic collaborations with other Programs, including Oncoimaging (Neoadjuvant breast), and Cacinogenesis and Signaling (CML, prostate). Over the past five years, our Program has focused on accrual to clinical research trials, including Hypothesis-driven, investigator-initiated trials (HDII), cooperative group, and pharmaceutical sponsored trials. Emphasis has been placed on HDII trials to exploit UCI's rich Comprehensive Cancer Center resources to develop novel approaches to cancer care. HDII accrual over the past six years has grown dramatically from 60 in 2002-2004 to 175 in 2005-2007. Overall interventional clinical trials accrual, excluding chemoprevention trials, was 142 in 2002-2003, increasing to 218 in 2004-2005, and 387 to date in 2005-2007, Of particular significance, this growth in accrual was linked to translational endpoints that led to peer reviewed funding and increased numbers of publications in high impact journals. The TO Program has 25 Members, representing eight Departments and one School, and has $2,024,203 in direct cancer-related peer-reviewed funding, 10 projects of which are funded by NCI for a direct total of $1,187,498. In 2007, Members published a total of 71 publications with 62 of those being cancer-related of which 44% were inter- and 16% were intra-related.